SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jay silberman who wrote (100)12/6/1996 12:40:00 AM
From: John Metcalf   of 6136
 
Why the rise ($4+)?

Some conjectures:

1) Technical bounce after a 20% retreat from $60. Profits were taken, then buyers emerged.

2) The biggie, IMHO: AGPH has been testing Viracept in children with HIV. Testing in kids is a new expectation of the FDA Subcommittee, and has recently been in the news, including a big WSJ article. This was part of a news story when the Anti-viral Subcommittee split 4-4 on Rescriptor:

>This approval application also highlighted a new focus in the decisions of the Antiviral Drugs Advisory Committee: pediatric usage. Panel chair Scott Hammer, associate professor of medicine at Harvard Medical School, in Cambridge, Mass., said the panel "preferred not to see another proposal for expedited approval for an AIDS drug without at the very least preliminary data in children."
>
>The panel noted that should the FDA choose to grant expedited approval for Rescriptor, the agency should require postmarketing evaluations of triple and 4-drug therapy as well as a study in children.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News